Drug intelligence / Profile preview

BRKB-101

Development stage: Discontinued
Lead developer: BrickBio
Modality: Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
Administration: Parenteral

Overview

BRKB-101 is a drug conjugate developed by BrickBio using its modular multisite platform (MMP). It was designed as an antineoplastic agent for the treatment of breast cancer and gastric (stomach) cancer. The precise mechanism of action has not been defined or disclosed publicly. As of the latest updates, development for this compound has been discontinued and it did not progress beyond early research or discovery phases[1][2].

Beyond the preview

Go deeper on BRKB-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRKB-101.

Explore the full profile